BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Takizawa D, Kakizaki S, Sohara N, Sato K, Takagi H, Arai H, Katakai K, Kojima A, Matsuzaki Y, Mori M. Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: Clinical Characteristics, Prognosis, and Patient Survival Analysis. Dig Dis Sci 2007;52:3290-5. [DOI: 10.1007/s10620-007-9808-2] [Cited by in Crossref: 94] [Cited by in F6Publishing: 85] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Yang P, Li QJ, Feng Y, Zhang Y, Markowitz GJ, Ning S, Deng Y, Zhao J, Jiang S, Yuan Y, Wang HY, Cheng SQ, Xie D, Wang XF. TGF-β-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell 2012;22:291-303. [PMID: 22975373 DOI: 10.1016/j.ccr.2012.07.023] [Cited by in Crossref: 317] [Cited by in F6Publishing: 318] [Article Influence: 31.7] [Reference Citation Analysis]
2 Chen Z, Xiang L, Huang Y, Fang Y, Li X, Yang D. [Expression of long noncoding RNA linc00261 in hepatocellular carcinoma and its association with postoperative outcomes]. Nan Fang Yi Ke Da Xue Xue Bao 2018;38:1179-86. [PMID: 30377132 DOI: 10.3969/j.issn.1673-4254.2018.10.05] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
3 Chang IS, Shin SW, Cho SK, Rhim H, Choi D, Park KB, Park HS, Choo SW, Do YS, Choo I. Evolution of portal vein tumor thromboses in patients with hepatocellular carcinoma: CT findings and transition of serum tumor markers. Clinical Imaging 2012;36:489-95. [DOI: 10.1016/j.clinimag.2011.11.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
4 Terashima T, Yamashita T, Iida N, Yamashita T, Nakagawa H, Arai K, Kitamura K, Kagaya T, Sakai Y, Mizukoshi E. Blood neutrophil to lymphocyte ratio as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy. Hepatol Res. 2015;45:949-959. [PMID: 25319848 DOI: 10.1111/hepr.12436] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
5 Kasai K, Ushio A, Kasai Y, Sawara K, Miyamoto Y, Oikawa K, Kuroda H, Takikawa Y, Suzuki K. Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion. Cancer. 2012;118:3302-3310. [PMID: 22072099 DOI: 10.1002/cncr.26648] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
6 Liu J, Wang Y, Zhang D, Liu B, Ou Q. Comparison of survival and quality of life of hepatectomy and thrombectomy using total hepatic vascular exclusion and chemotherapy alone in patients with hepatocellular carcinoma and tumor thrombi in the inferior vena cava and hepatic vein. Eur J Gastroenterol Hepatol. 2012;24:186-194. [PMID: 22081008 DOI: 10.1097/meg.0b013e32834dda64] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
7 Ventura P, Venturelli G, Marcacci M, Fiorini M, Marchini S, Cuoghi C, Pietrangelo A. Hyperhomocysteinemia and MTHFR C677T polymorphism in patients with portal vein thrombosis complicating liver cirrhosis. Thromb Res. 2016;141:189-195. [PMID: 27065203 DOI: 10.1016/j.thromres.2016.03.024] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
8 Lv WF, Liu KC, Lu D, Zhou CZ, Cheng DL, Xiao JK, Zhang XM, Zhang ZF. Transarterial chemoembolization for hepatocellular carcinoma combined with portal vein tumor thrombosis. Cancer Manag Res 2018;10:4719-26. [PMID: 30410405 DOI: 10.2147/CMAR.S166527] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
9 Nagamatsu H, Sumie S, Niizeki T, Tajiri N, Iwamoto H, Aino H, Nakano M, Shimose S, Satani M, Okamura S. Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma: multicenter phase II study. Cancer Chemother Pharmacol. 2016;77:243-250. [PMID: 26754678 DOI: 10.1007/s00280-015-2892-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
10 Giorgio A, Calisti G, Montesarchio L, Scognamiglio U, Matteucci P, Coppola C, Scarano F, Amendola F, Giorgio V. Hepatocellular carcinoma invading portal venous system in cirrhosis: long term results of percutaneous radiofrequency ablation of both the nodule and portal vein tumor thrombus. A case control study. Anticancer Res. 2014;34:6785-6790. [PMID: 25368292 DOI: 10.2214/ajr.08.2087] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
11 Thanos L, Sotiropoulou E, Tanteles S, Pomoni M, Kelekis D. Direct Radiofrequency Ablation of Portal Vein Tumor Thrombus in Continuity with Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology 2010;21:285-8. [DOI: 10.1016/j.jvir.2009.10.034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
12 Akin O, Dixit D, Schwartz L. Bland and tumor thrombi in abdominal malignancies: magnetic resonance imaging assessment in a large oncologic patient population. Abdom Imaging. 2011;36:62-68. [PMID: 20225091 DOI: 10.1007/s00261-010-9608-6] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
13 Wu TT, Li HC, Zheng F, Ao GK, Lin H, Li WM. Percutaneous Endovascular Radiofrequency Ablation for Malignant Portal Obstruction: An Initial Clinical Experience. Cardiovasc Intervent Radiol 2016;39:994-1000. [PMID: 26943811 DOI: 10.1007/s00270-016-1317-2] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
14 Jha RC, Khera SS, Kalaria AD. Portal Vein Thrombosis: Imaging the Spectrum of Disease With an Emphasis on MRI Features. American Journal of Roentgenology 2018;211:14-24. [DOI: 10.2214/ajr.18.19548] [Cited by in Crossref: 22] [Cited by in F6Publishing: 4] [Article Influence: 5.5] [Reference Citation Analysis]
15 Chen CS, Li FK, Guo CY, Xiao JC, Hu HT, Cheng HT, Zheng L, Zong DW, Ma JL, Jiang L, Li HL. Tumor vascularity and lipiodol deposition as early radiological markers for predicting risk of disease progression in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization. Oncotarget 2016;7:7241-52. [PMID: 26769845 DOI: 10.18632/oncotarget.6892] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
16 Zhang ZM, Lai EC, Zhang C, Yu HW, Liu Z, Wan BJ, Liu LM, Tian ZH, Deng H, Sun QH, Chen XP. The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus. Int J Surg 2015;20:8-16. [PMID: 26026424 DOI: 10.1016/j.ijsu.2015.05.009] [Cited by in Crossref: 50] [Cited by in F6Publishing: 57] [Article Influence: 7.1] [Reference Citation Analysis]
17 Xiao L, Liu Q, Zhao W, Pang H, Zeng Q, Chen Y, Zhao J, Mei Q, He X. Chemoembolisation with polyvinyl alcohol for advanced hepatocellular carcinoma with portal vein tumour thrombosis and arterioportal shunts: efficacy and prognostic factors. Clin Radiol 2018;73:1056.e17-22. [PMID: 30224186 DOI: 10.1016/j.crad.2018.08.002] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Zhou L, Rui J, Wang S, Chen S, Qu Q. Clinicopathological Predictors of Poor Survival and Recurrence After Curative Resection in Hepatocellular Carcinoma Without Portal Vein Tumor Thrombosis. Pathol Oncol Res 2015;21:131-8. [DOI: 10.1007/s12253-014-9798-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
19 Liberati S, Morelli MB, Amantini C, Farfariello V, Santoni M, Conti A, Nabissi M, Cascinu S, Santoni G. Loss of TRPV2 Homeostatic Control of Cell Proliferation Drives Tumor Progression. Cells 2014;3:112-28. [PMID: 24709905 DOI: 10.3390/cells3010112] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
20 Chen J, Shi X, Luo T, Zhao Y, Ye J, Bai T, Li L. The correlations between hepatitis B virus infection and hepatocellular carcinoma with portal vein tumor thrombus or extrahepatic metastasis. Eur J Gastroenterol Hepatol 2020;32:373-7. [PMID: 31441795 DOI: 10.1097/MEG.0000000000001514] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Mantaka A, Augoustaki A, Kouroumalis EA, Samonakis DN. Portal vein thrombosis in cirrhosis: diagnosis, natural history, and therapeutic challenges. Ann Gastroenterol 2018;31:315-29. [PMID: 29720857 DOI: 10.20524/aog.2018.0245] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
22 Zeng ZC, Fan J, Tang ZY, Zhou J, Wang JH, Wang BL, Guo W. Prognostic factors for patients with hepatocellular carcinoma with macroscopic portal vein or inferior vena cava tumor thrombi receiving external-beam radiation therapy. Cancer Sci. 2008;99:2510-2517. [PMID: 19032365 DOI: 10.1111/j.1349-7006.2008.00981.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
23 Qiu B, Li K, Dong X, Liu FQ. Transjugular Intrahepatic Portosystemic Shunt for Portal Hypertension in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Cardiovasc Intervent Radiol. 2017;40:1372-1382. [PMID: 28488102 DOI: 10.1007/s00270-017-1655-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
24 Ni FB, Lin Z, Fan XH, Shi KQ, Ao JY, Wang XD, Chen RC. A novel genomic-clinicopathologic nomogram to improve prognosis prediction of hepatocellular carcinoma. Clin Chim Acta 2020;504:88-97. [PMID: 32032609 DOI: 10.1016/j.cca.2020.02.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
25 Zhuang LP, Meng ZQ. Serum miR-224 reflects stage of hepatocellular carcinoma and predicts survival. Biomed Res Int. 2015;2015:731781. [PMID: 25688365 DOI: 10.1155/2015/731781] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
26 Kim JW, Lee BC, Shin SS, Heo SH, Lim HS, Jeong YY, Kang HK, Hur YH, Choi YD. Rapidly progressive hepatocellular carcinoma mimicking benign portal vein thrombosis: a case report. Gut Liver 2013;7:116-9. [PMID: 23423240 DOI: 10.5009/gnl.2013.7.1.116] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
27 Tsai AL, Burke CT, Kennedy AS, Moore DT, Mauro MA, Dixon RD, Stavas JM, Bernard SA, Khandani AH, O’Neil BH. Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol. 2010;21:1377-1384. [PMID: 20691606 DOI: 10.1016/j.jvir.2010.04.027] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
28 Sun L, Guan YS, Pan WM, Chen GB, Luo ZM, Wei JH, Wu H. Highly metabolic thrombus of the portal vein: 18F fluorodeoxyglucose positron emission tomography/computer tomography demonstration and clinical significance in hepatocellular carcinoma. World J Gastroenterol 2008; 14(8): 1212-1217 [PMID: 18300346 DOI: 10.3748/wjg.14.1212] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
29 Zheng JS, Long J, Sun B, Lu NN, Fang D, Zhao LY, Du N. Transcatheter arterial chemoembolization combined with radiofrequency ablation can improve survival of patients with hepatocellular carcinoma with portal vein tumour thrombosis: extending the indication for ablation? Clin Radiol. 2014;69:e253-e263. [PMID: 24581962 DOI: 10.1016/j.crad.2014.01.015] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
30 Catalano OA, Choy G, Zhu A, Hahn PF, Sahani DV. Differentiation of malignant thrombus from bland thrombus of the portal vein in patients with hepatocellular carcinoma: application of diffusion-weighted MR imaging. Radiology. 2010;254:154-162. [PMID: 20032150 DOI: 10.1148/radiol.09090304] [Cited by in Crossref: 128] [Cited by in F6Publishing: 114] [Article Influence: 10.7] [Reference Citation Analysis]
31 He X, Li J, Guo W, Liu W, Yu J, Song W, Dong L, Wang F, Yu S, Zheng Y, Chen S, Kong Y, Liu C. Targeting the microRNA-21/AP1 axis by 5-fluorouracil and pirarubicin in human hepatocellular carcinoma. Oncotarget 2015;6:2302-14. [PMID: 25544773 DOI: 10.18632/oncotarget.2955] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
32 Tang A, Cruite I, Sirlin CB. Toward a standardized system for hepatocellular carcinoma diagnosis using computed tomography and MRI. Expert Rev Gastroenterol Hepatol. 2013;7:269-279. [PMID: 23445236 DOI: 10.1586/egh.13.3] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
33 Agarwal KK, Shah D, Shah N, Mayank M. Differentiation of Malignant Thrombus From Bland Thrombus of the Portal Vein in Patient With Hepatocellular Carcinoma on 18F-FDG PET CT. Clin Nucl Med. 2017;42:e472-e474. [PMID: 28922192 DOI: 10.1097/rlu.0000000000001840] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Nagamatsu H, Hiraki M, Mizukami N, Yoshida H, Iwamoto H, Sumie S, Torimura T, Sata M. Intra-arterial therapy with cisplatin suspension in lipiodol and 5-fluorouracil for hepatocellular carcinoma with portal vein tumour thrombosis. Aliment Pharmacol Ther. 2010;32:543-550. [PMID: 20500734 DOI: 10.1111/j.1365-2036.2010.04379.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
35 Zhang ZY, Dong KS, Zhang EL, Zhang LW, Chen XP, Dong HH. Resection might be a meaningful choice for hepatocellular carcinoma with portal vein thrombosis: A systematic review and meta-analysis. Medicine (Baltimore) 2019;98:e18362. [PMID: 31852141 DOI: 10.1097/MD.0000000000018362] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
36 Long J, Zheng J, Sun B, Lu N. Microwave ablation of hepatocellular carcinoma with portal vein tumor thrombosis after transarterial chemoembolization: a prospective study. Hepatol Int 2016;10:175-84. [DOI: 10.1007/s12072-015-9673-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
37 Wu B, Zhang Y, Tan H, Shi H. Value of 18F-FDG PET/CT in the diagnosis of portal vein tumor thrombus in patients with hepatocellular carcinoma. Abdom Radiol (NY) 2019;44:2430-5. [PMID: 30944961 DOI: 10.1007/s00261-019-01997-2] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
38 Liu M, Shi J, Mou T, Wang Y, Wu Z, Shen A. Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis. J Gastroenterol Hepatol. 2020;35:1277-1287. [PMID: 32052876 DOI: 10.1111/jgh.15010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
39 Wang T, Hu HS, Feng YX, Shi J, Li N, Guo WX, Xue J, Xie D, Liu SR, Wu MC, Cheng SQ. Characterisation of a novel cell line (CSQT-2) with high metastatic activity derived from portal vein tumour thrombus of hepatocellular carcinoma. Br J Cancer 2010;102:1618-26. [PMID: 20461085 DOI: 10.1038/sj.bjc.6605689] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 3.4] [Reference Citation Analysis]
40 Okazaki E, Yamamoto A, Nishida N, Hamuro M, Ogino R, Hosono M, Shimatani Y, Tsutsumi S, Hamamoto S, Sohgawa E, Jogo A, Miki Y. Three-dimensional conformal radiotherapy for locally advanced hepatocellular carcinoma with portal vein tumour thrombosis: evaluating effectiveness of the model for end-stage liver disease (MELD) score compared with the Child-Pugh classification. Br J Radiol 2016;89:20150945. [PMID: 27164029 DOI: 10.1259/bjr.20150945] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
41 Ahn JH, Yu JS, Cho ES, Chung JJ, Kim JH, Kim KW. Diffusion-Weighted MRI of Malignant versus Benign Portal Vein Thrombosis. Korean J Radiol 2016;17:533-40. [PMID: 27390544 DOI: 10.3348/kjr.2016.17.4.533] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
42 Koh YX, Tan HL, Lye WK, Kam JH, Chiow AKH, Tan SS, Choo SP, Chung AYF, Goh BKP. Systematic review of the outcomes of surgical resection for intermediate and advanced Barcelona Clinic Liver Cancer stage hepatocellular carcinoma: A critical appraisal of the evidence. World J Hepatol 2018; 10(6): 433-447 [PMID: 29988922 DOI: 10.4254/wjh.v10.i6.433] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
43 Chammas MC, Oliveira AC, D Ávilla MJ, Moraes PH, Takahashi MS. Characterization of Malignant Portal Vein Thrombosis with Contrast-Enhanced Ultrasonography. Ultrasound Med Biol 2019;45:50-5. [PMID: 30366607 DOI: 10.1016/j.ultrasmedbio.2018.09.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
44 Su T, He W, Jin L, Chen G, Xiao G. Early Response of Hepatocellular Carcinoma to Chemoembolization: Volume Computed Tomography Liver Perfusion Imaging as a Short-Term Response Predictor. Journal of Computer Assisted Tomography 2017;41:315-20. [DOI: 10.1097/rct.0000000000000511] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
45 Karaosmanoglu AD, Onur MR, Uysal A, Akata D, Ozmen MN, Karcaaltincaba M. Tumor in the veins: an abdominal perspective with an emphasis on CT and MR imaging. Insights Imaging 2020;11:52. [PMID: 32215762 DOI: 10.1186/s13244-020-00854-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
46 Lai HC, Lee MS, Lin C, Lin KT, Huang YH, Wong CS, Chan SM, Wu ZF. Propofol-based total intravenous anaesthesia is associated with better survival than desflurane anaesthesia in hepatectomy for hepatocellular carcinoma: a retrospective cohort study. Br J Anaesth. 2019;123:151-160. [PMID: 31171343 DOI: 10.1016/j.bja.2019.04.057] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
47 Asiyanbola B, Chang D, Gleisner AL, Nathan H, Choti MA, Schulick RD, Pawlik TM. Operative mortality after hepatic resection: are literature-based rates broadly applicable? J Gastrointest Surg. 2008;12:842-851. [PMID: 18266046 DOI: 10.1007/s11605-008-0494-y] [Cited by in Crossref: 114] [Cited by in F6Publishing: 111] [Article Influence: 8.1] [Reference Citation Analysis]
48 Kim JH, Lee JM, Yoon JH, Lee DH, Lee KB, Han JK, Choi BI. Portal Vein Thrombosis in Patients with Hepatocellular Carcinoma: Diagnostic Accuracy of Gadoxetic Acid-enhanced MR Imaging. Radiology. 2016;279:773-783. [PMID: 26780538 DOI: 10.1148/radiol.2015150124] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
49 Jian J, Yang H, Zhao X, Xuan R, Zhang Y, Li D, Hu C. Visualization of microvasculature and thrombi by X-ray phase-contrast computed tomography in hepatocellular carcinoma. J Synchrotron Radiat 2016;23:600-5. [PMID: 26917149 DOI: 10.1107/S1600577516001016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
50 Terashima T, Honda M, Toyama T, Shimakami T, Shimizu R, Takatori H, Arai K, Kawaguchi K, Kitamura K, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Kaneko S. IL-28B variant as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy. J Gastroenterol Hepatol 2020;35:1813-20. [PMID: 32180251 DOI: 10.1111/jgh.15035] [Reference Citation Analysis]
51 Hou JZ, Zeng ZC, Zhang JY, Fan J, Zhou J, Zeng MS. Influence of tumor thrombus location on the outcome of external-beam radiation therapy in advanced hepatocellular carcinoma with macrovascular invasion. Int J Radiat Oncol Biol Phys. 2012;84:362-368. [PMID: 22381903 DOI: 10.1016/j.ijrobp.2011.12.024] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
52 Terashima T, Yamashita T, Horii R, Arai K, Kawaguchi K, Kitamura K, Yamashita T, Sakai Y, Mizukoshi E, Honda M, Kaneko S. Potential efficacy of therapies targeting intrahepatic lesions after sorafenib treatment of patients with hepatocellular carcinoma. BMC Cancer 2016;16:338. [PMID: 27246496 DOI: 10.1186/s12885-016-2380-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
53 Kim SH, Oh JS, Chun HJ, Choi BG, Lee HG. Dual-Port versus Mono-Port Implantation for Intra-Arterial Chemoinfusion Therapy for Treatment of Hepatocellular Carcinoma in Patients with Anatomic Hepatic Artery Variation. J Vasc Interv Radiol. 2019;30:23-30. [PMID: 30297310 DOI: 10.1016/j.jvir.2018.06.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
54 Liao Y, Zheng Y, He W, Li Q, Shen J, Hong J, Zou R, Qiu J, Li B, Yuan Y. Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence. Oncol Lett 2017;13:984-92. [PMID: 28356989 DOI: 10.3892/ol.2016.5525] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
55 Li C, Hu J, Zhou D, Zhao J, Ma K, Yin X, Wang J. Differentiation of bland from neoplastic thrombus of the portal vein in patients with hepatocellular carcinoma: application of susceptibility-weighted MR imaging. BMC Cancer. 2014;14:590. [PMID: 25123782 DOI: 10.1186/1471-2407-14-590] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
56 Zhu K, Meng X, Zhou B, Qian J, Huang W, Deng M, Shan H. Percutaneous transsplenic portal vein catheterization: technical procedures, safety, and clinical applications. J Vasc Interv Radiol. 2013;24:518-527. [PMID: 23522157 DOI: 10.1016/j.jvir.2012.12.028] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
57 Agrawal A, Purandare N, Shah S, Puranik A, Rangarajan V. Extensive tumor thrombus of hepatocellular carcinoma in the entire portal venous system detected on fluorodeoxyglucose positron emission tomography computed tomography. Indian J Nucl Med 2013;28:54-6. [PMID: 24019682 DOI: 10.4103/0972-3919.116805] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
58 Baek YH, Kim KT, Lee SW, Jeong JS, Park BH, Nam KJ, Cho JH, Kim YH, Roh YH, Lee HS, Choi YM, Han SY. Efficacy of hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma. World J Gastroenterol 2012; 18(26): 3426-3434 [PMID: 22807613 DOI: 10.3748/wjg.v18.i26.3426] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
59 Raza SA, Jang HJ, Kim TK. Differentiating malignant from benign thrombosis in hepatocellular carcinoma: contrast-enhanced ultrasound. Abdom Imaging. 2014;39:153-161. [PMID: 24002440 DOI: 10.1007/s00261-013-0034-4] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 6.1] [Reference Citation Analysis]
60 Hirooka M, Koizumi Y, Kisaka Y, Abe M, Murakami H, Matsuura B, Hiasa Y, Onji M. Mass reduction by radiofrequency ablation before hepatic arterial infusion chemotherapy improved prognosis for patients with huge hepatocellular carcinoma and portal vein thrombus. AJR Am J Roentgenol. 2010;194:W221-W226. [PMID: 20093578 DOI: 10.2214/ajr.09.2852] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
61 Liu J, Ladbury C, Amini A, Glaser S, Kessler J, Lee A, Chen YJ. Combination of yttrium-90 radioembolization with stereotactic body radiation therapy in the treatment of portal vein tumor thrombosis. Radiat Oncol J 2021;39:113-21. [PMID: 34619828 DOI: 10.3857/roj.2021.00213] [Reference Citation Analysis]
62 Subbotin VM. Privileged portal metastasis of hepatocellular carcinoma in light of the coevolution of a visceral portal system and liver in the chordate lineage: a search for therapeutic targets. Drug Discov Today 2018;23:548-64. [PMID: 29330122 DOI: 10.1016/j.drudis.2018.01.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
63 Cruite I, Tang A, Sirlin CB. Imaging-based diagnostic systems for hepatocellular carcinoma. AJR Am J Roentgenol. 2013;201:41-55. [PMID: 23789657 DOI: 10.2214/ajr.13.10570] [Cited by in Crossref: 52] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
64 Osman NMM, Samy LAM. Benign and malignant portal venous thrombosis: Multi-modality imaging evaluation. The Egyptian Journal of Radiology and Nuclear Medicine 2016;47:387-97. [DOI: 10.1016/j.ejrnm.2016.02.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
65 Ayyappan AP, Jhaveri KS. CT and MRI of hepatocellular carcinoma: an update. Expert Rev Anticancer Ther. 2010;10:507-519. [PMID: 20397916 DOI: 10.1586/era.10.24] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
66 Lin CC, Hung CF, Chen WT, Lin SM. Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: Impact of Early Response to 4 Weeks of Treatment. Liver Cancer 2015;4:228-40. [PMID: 26734578 DOI: 10.1159/000367737] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
67 Liu YE, Zong J, Ren XC, Lin Q. High-intensity focused ultrasound combined with transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma: A case report. Medicine (Baltimore) 2019;98:e16660. [PMID: 31374039 DOI: 10.1097/MD.0000000000016660] [Reference Citation Analysis]
68 Shim M, Yang TY, Cho NG, Woo A, Kim E, Park K, Lee JH, Lee YB, Hwang SG, Rim KS, Park H. Hepatic Infarction Caused by Portal Vein Thrombophlebitis Misdiagnosed as Infiltrative Hepatic Malignancy with Neoplastic Thrombus. Korean J Gastroenterol 2016;68:156-60. [PMID: 27646586 DOI: 10.4166/kjg.2016.68.3.156] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
69 Luo J, Xu L, Li L, Zhang J, Zhang M, Xu M. Comparison of treatments for hepatocellular carcinoma patients with portal vein thrombosis: a systematic review and network meta-analysis. Ann Transl Med 2021;9:1450. [PMID: 34734002 DOI: 10.21037/atm-21-3937] [Reference Citation Analysis]
70 Zhang XB, Wang JH, Yan ZP, Qian S, Du SS, Zeng ZC. Hepatocellular carcinoma with main portal vein tumor thrombus: treatment with 3-dimensional conformal radiotherapy after portal vein stenting and transarterial chemoembolization. Cancer. 2009;115:1245-1252. [PMID: 19156918 DOI: 10.1002/cncr.24139] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 4.1] [Reference Citation Analysis]
71 Pregler B, Beyer LP, Wiesinger I, Haimerl M, Stroszczynski C, Jung EM, Wiggermann P. Reduced microperfusion due to portal vein thrombosis: Impact on the outcome of percutaneous thermal tumor ablation. Clin Hemorheol Microcirc 2017;67:383-8. [PMID: 28885205 DOI: 10.3233/CH-179218] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
72 Terashima T, Yamashita T, Takata N, Nakagawa H, Toyama T, Arai K, Kitamura K, Yamashita T, Sakai Y, Mizukoshi E, Honda M, Kaneko S. Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib: PPS in advanced HCC treated by sorafenib. Hepatol Res 2016;46:650-6. [DOI: 10.1111/hepr.12601] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
73 Gawande R, Jalaeian H, Niendorf E, Olgun D, Krystosek L, Rubin N, Spilseth B. MRI in differentiating malignant versus benign portal vein thrombosis in patients with hepatocellular carcinoma: Value of post contrast imaging with subtraction. Eur J Radiol 2019;118:88-95. [PMID: 31439264 DOI: 10.1016/j.ejrad.2019.07.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
74 Pleguezuelo M, Germani G, Marelli L, Xiruochakis E, Misseri M, Manousou P, Arvaniti V, Burroughs AK. Evidence-based diagnosis and locoregional therapy for hepatocellular carcinoma. Expert Review of Gastroenterology & Hepatology 2014;2:761-84. [DOI: 10.1586/17474124.2.6.761] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
75 Li SH, Wang QX, Sun P, Li Q, Yang ZY, Shi M, Wei W, Guo RP. Surgical Strategy for Hepatocellular Carcinoma Patients with Portal/Hepatic Vein Tumor Thrombosis. PLoS One. 2015;10:e0130021. [PMID: 26076461 DOI: 10.1371/journal.pone.0130021] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
76 Sandrasegaran K, Tahir B, Nutakki K, Akisik FM, Bodanapally U, Tann M, Chalasani N. Usefulness of conventional MRI sequences and diffusion-weighted imaging in differentiating malignant from benign portal vein thrombus in cirrhotic patients. AJR Am J Roentgenol. 2013;201:1211-1219. [PMID: 24261359 DOI: 10.2214/ajr.12.10171] [Cited by in Crossref: 58] [Cited by in F6Publishing: 15] [Article Influence: 7.3] [Reference Citation Analysis]
77 Moriguchi M, Furuta M, Itoh Y. A Review of Non-operative Treatments for Hepatocellular Carcinoma with Advanced Portal Vein Tumor Thrombus. J Clin Transl Hepatol 2017;5:177-83. [PMID: 28660156 DOI: 10.14218/JCTH.2016.00075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
78 Liu QS, Mei QL, Li YH. Polyvinyl alcohol terminal chemoembolization for hepatocellular carcinoma with hepatic arteriovenous shunts: Safety, efficacy, and prognostic factors. Eur J Radiol 2017;89:277-83. [PMID: 27908612 DOI: 10.1016/j.ejrad.2016.04.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
79 Terashima T, Yamashita T, Arai K, Sunagozaka H, Kitahara M, Nakagawa H, Kagaya T, Mizukoshi E, Honda M, Kaneko S. Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib. Hepatol Res 2014;44:1179-85. [PMID: 24171787 DOI: 10.1111/hepr.12266] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
80 Leroux C, Vauléon E, Pracht M, Zoheir Y, Boucher E, Audrain O, Raoul JL. Impressive efficacy of sorafenib in a patient with an hepatocellular carcinoma and a portal vein thrombosis associated with a metastatic ENT cancer. Med Oncol 2011;28 Suppl 1:S246-9. [PMID: 20936376 DOI: 10.1007/s12032-010-9708-8] [Reference Citation Analysis]
81 Liu G, Xie C, Sun F, Xu X, Yang Y, Zhang T, Deng Y, Wang D, Huang Z, Yang L, Huang S, Wang Q, Liu G, Zhong D, Miao X. Clinical significance of transient receptor potential vanilloid 2 expression in human hepatocellular carcinoma. Cancer Genetics and Cytogenetics 2010;197:54-9. [DOI: 10.1016/j.cancergencyto.2009.08.007] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
82 Kaufmann S, Schulze M, Spira D, Horger M. Modern multimodality diagnosis of portal vein infiltration in hepatocellular carcinoma and expected changes during current therapies. Acta Radiol 2015;56:1283-92. [DOI: 10.1177/0284185114556305] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
83 Mahmood K, Naqvi IH, Mahmood A, Muhammad S, Muhammad N. Deal a death blow! HCC in cirrhotics - thrombotic complications: their frequency, characteristics, and risk factors. Prz Gastroenterol 2018;13:52-60. [PMID: 29657612 DOI: 10.5114/pg.2018.74566] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
84 Kim TK, Jang H, Wilson SR. Ultrasound of Hepatocellular Carcinoma: The Important Contribution of Contrast Enhancement. In: Carr BI, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2016. pp. 367-90. [DOI: 10.1007/978-3-319-34214-6_24] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
85 Xu X, Wei X, Ling Q, Cheng J, Zhou B, Xie H, Zhou L, Zheng S. Identification of two portal vein tumor thrombosis associated proteins in hepatocellular carcinoma: Protein disulfide-isomerase A6 and apolipoprotein A-I: Protein disulfide isomerase A6 and apolipoprotein A-I. Journal of Gastroenterology and Hepatology 2011;26:1787-94. [DOI: 10.1111/j.1440-1746.2011.06796.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
86 Aumann EK, Server S, Koyuncu Sokmen B, Oz A, Namal E, Gurcan NI, Balci NC, Tokat Y. Diagnostic performances of intravoxel incoherent motion and conventional diffusion-weighted imaging in the differential diagnosis of benign and malignant portal vein thrombus. Abdom Radiol (NY) 2018;43:2270-6. [PMID: 29411058 DOI: 10.1007/s00261-018-1467-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
87 Tang A, Valasek MA, Sirlin CB. Update on the Liver Imaging Reporting and Data System: What the Pathologist Needs to Know. Adv Anat Pathol. 2015;22:314-322. [PMID: 26262514 DOI: 10.1097/pap.0000000000000089] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
88 Subbotin VM. A hypothesis on paradoxical privileged portal vein metastasis of hepatocellular carcinoma. Can organ evolution shed light on patterns of human pathology, and vice versa? Med Hypotheses 2019;126:109-28. [PMID: 31010487 DOI: 10.1016/j.mehy.2019.03.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
89 Hu S, Zhang J, Cheng C, Liu Q, Sun G, Zuo C. The role of 18F-FDG PET/CT in differentiating malignant from benign portal vein thrombosis. Abdom Imaging. 2014;39:1221-1227. [PMID: 24913670 DOI: 10.1007/s00261-014-0170-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
90 Imai Y, Hirooka M, Koizumi Y, Nakamura Y, Watanabe T, Yoshida O, Tokumoto Y, Takeshita E, Abe M, Tanaka H, Kurata M, Kitazawa S, Hiasa Y. Histological assessment of the efficacy of drug-eluting beads in portal tumor thrombosis of hepatocellular carcinoma. Radiol Case Rep 2017;12:179-84. [PMID: 28228906 DOI: 10.1016/j.radcr.2016.11.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]